Brief: Aptose Biosciences Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
05/04/2024 22:35
April 5 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE BIOSCIENCES INC: ON APRIL 2, RECEIVED NOTICE OF
DELISTING
OR FAILURE TO SATISFY CONTINUED LISTING RULE OR STANDARD FROM
NASDAQ
Source text for Eikon: ID:n0001171843-24-001877
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting